PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF
申请人:Kawazoe Kentaro
公开号:US20120178931A1
公开(公告)日:2012-07-12
Provided is a process by which pyrimidinylacetonitrile derivatives can be prepared easily and efficiently from industrially available raw materials. Also provided are intermediates for the synthesis of the derivatives. A process for the preparation of pyrimidinylacetonitrile derivatives represented by general formula (3) [wherein X is a halogen atom, and R is an alkoxymethyl group], characterized by reacting a 2,4-dihalogeno-6-nitrobenzene derivative represented by general formula (1) [wherein X and R are each as defined above] with 4,6-dimethoxy-2-cyanomethylpyrimidine represented by general formula (2) [wherein Me represents a methyl group] in the presence of a base; and intermediates for the synthesis of the pyrimidinylacetonitrile derivatives.
SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS
申请人:Bristol-Myers Squibb Company
公开号:US20140378475A1
公开(公告)日:2014-12-25
Disclosed are compounds of Formula (I)
wherein: the two dotted lines represent either two single or two double bonds; Q is:
R
1
is F, Cl, —CN, or —CH
3
; R
2
is Cl or —CH
3
; R
3
is —C(CH
3
)
2
OH or —CH
2
CH
2
OH; R
a
is H or —CH
3
; each R
b
is independently F, Cl, —CH
3
, and/or —OCH
3
; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
Bicyclic And Tricyclic Compounds As KAT II Inhibitors
申请人:Claffey Michelle M.
公开号:US20100324043A1
公开(公告)日:2010-12-23
Compounds of Formula X:
wherein A, X, Y, Z, R
5
, R
6a
, and R
6b
are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.
Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
申请人:Mjalli M.M. Adnan
公开号:US20060223849A1
公开(公告)日:2006-10-05
The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.
Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors
申请人:Mjalli Adnan M.M.
公开号:US20090326006A1
公开(公告)日:2009-12-31
The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.